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Herring-roe, which contains large amounts of docosahexaenoic acid and eicosapentaenoic acid, has anti-
dyslipidemia effects. Here, we evaluated the effects of herring-roe on lipid metabolism in 33 adult
subjects in a randomized, double-blind, placebo-controlled study. We divided the subjects into a test
group that ingested herring-roe lyophilized powder (herring-roe powder) and a placebo group that
ingested non-herring-roe powder, with each member of each group ingesting 15 g daily for 8 weeks.
Hematological tests and body composition measurements were performed before and after 4, 6, and 8
weeks of the study period. Although no signiﬁcant differences in low density lipoprotein were observed,
high density lipoprotein was found to be increased in subjects who ingested herring-roe powder. In
addition, the level of free fatty acid was signiﬁcantly improved in the herring-roe powder group. These
results suggest that ingestion of herring-roe could inﬂuence lipid metabolism.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the past few decades, the prevalence of dyslipidemia has
markedly increased worldwide, particularly in wealthy industrial-
ized countries such as Japan.1 Most large-scale and long-term
cohort studies over the past 5e20 years have indicated that a diet
rich in animal fat was associated with higher all-cause mortality.2
High-fat westernized diets have been implicated in the increasing
prevalence of dyslipidemia, a risk factor of atherosclerosis.3 Thus, it
is important to investigate the utility of functional foods and the
bioactive components of food to improve and prevent dyslipidemia.
Fish oil contains rich polyunsaturated fatty acids (PUFAs),
particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA).4 EPA and DHA have a number of reported health beneﬁts in
humans, such as decreasing blood triglyceride concentrations in
hypertriglycemic patients and providing protective effects againstanagement and Informatics,
, Ebetsu 069-8585, Hokkaido,
ihira).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).cardiovascular diseases.5 This has led to recommendations from
health agencies worldwide to increase dietary intake of these fatty
acids.6 The mechanism of DHA and EPA for improvement of lipid
metabolism is the downregulation of the mature form of Sterol
Regulatory Element-Binding Proteins (SREBP)-1 by decreasing
SREBP-1c mRNA expression, with corresponding decreases of
mRNAs of cholesterologenic and lipogenic enzymes.7 In addition,
DHA and EPA facilitate b-oxidation of fatty acid.8 The Ministry of
Health, Labour and Welfare recommended that adult intakes more
than 1 g of DHA and EPA per day; however, dietary intake of DHA
and EPA was not sufﬁcient in Japanese people, possibly because of
decreased ﬁsh intake in Japan. Thus, it is important to research
functional foods to supplement DHA and EPA intake.
Herring-roe lipids contain a large amount of EPA and DHA. In
addition, DHA and EPA are the major molecular constituents in the
phosphatidylcholine of herring-roe.9 Therefore, DHA and EPA
contained in herring-roe is stable and difﬁcult to oxidize. Moreover,
herring-roe contains little cholesterol compared with that of other
ﬁsh roe (260 mg cholesterol per 100 g herring-roe).
These ﬁndings suggest that herring-roe, which is rich in DHA and
EPA and phosphatidylcholine-contained DHA and EPA, improves
lipid metabolism. However, the clinical studies assessing herring-roe
are very few. Here, we evaluated whether the ingestion of the
herring-roepowder can improvedyslipidemia inanadult population.rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
Table 2
Characteristics of the subjects in the placebo and herring-roe powder intake groups.
Characteristic Herring-roe Placebo P-value
Number of subjects n ¼ 17 n ¼ 16 e
Number of males (male %) 4 (76.47%) 2 (87.50%) 0.656
Age (years) 51.71 ± 9.25 53.19 ± 9.31 0.650
Height (cm) 158.43 ± 7.93 159.8 ± 5.00 0.560
Body weight (kg) 52.39 ± 9.74 58.93 ± 10.34 0.071
BMI (kg/m2) 20.73 ± 2.08 23.04 ± 3.69 0.033
Body fat percentage (%) 25.21 ± 5.42 30.18 ± 7.57 0.037
Values shown are mean ± standard deviation (SD). Statistical analysis was per-
formed by analysis of variance (ANOVA) for age, height, body weight, and BMI, and
by chi-square test for gender.
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2.1. Test meal preparation and ingestion method
The composition of herring-roe powder used in this study is
given in Table 1. Herring-roe was ﬁshed in Sitka, Alaska, USA. The
test meal was prepared by freeze-drying in a conventional method.
The production and packing was performed at Ihara Suisan Co., Ltd.
(FM96883/ISO9001 certiﬁcation).
The subjectswere instructed to ingest 15 g per dayof herring-roe
lyophilized powder (herring-roe powder) (containing DHA 540 mg
and EPA 300 mg) or a placebo powder (11 g of unpolished rice
powder containing 4 g of soybean curd used to imitate the texture
and appearance of herring-roe powder) in two parts per day.
2.2. Study subjects
Thirty-three volunteers (6 males and 27 females, age 40e67
years) were enrolled in this study. None had a recent history of
gastrointestinal disorders, pregnancy, signiﬁcant disease, surgery,
severe allergic reaction to food, or current use of any medication,
including anti-hyperlipidemia medication. The subjects' age, body
weight, height, body mass index (BMI), and body fat percentage are
listed in Table 2.
The clinical intervention was conducted as a double-blind, pla-
cebo-controlled trial. At randomization, the 33 eligible subjects
were blindly assigned to one of two groups: the test group who
ingested herring-roe powder and the placebo group who ingested
the placebo powder. The time schedule of this clinical study is
shown in Fig. 1.
We performed hematological examinations and body compo-
sition (body weight, BMI, and body fat rate) measurements at the
baseline (0 week) and post-intervention (4, 6, and 8 weeks) for the
two groups. The hematological examinations were consigned to
Sapporo Clinical Laboratory Inc. (Sapporo, Japan). Leptin and adi-
ponectin was measured by the Human Leptin Quantikine ELISA Kit
and the Human Total Adiponectin/Acrp30 Quantikine ELISA Kit
(R&D Systems, Minneapolis, MN, USA). The subjects' body
composition and blood pressure were measured with an In-Body
device (Biospace Co., Tokyo) and an Omron HEM-780 automatic
blood pressure monitor (Omron Corp., Kyoto, Japan).
All subjects provided written informed consent prior to under-
going any study-related tests, and the protocol was approved by the
Ethics Committee of Hokkaido Information University (a certiﬁcate
number; 2014-01). The study protocol conformed to the Helsinki
Declaration and registered at the UMIN Clinical Trial Registration
System (a certiﬁcate number; UMIN000017072).
2.3. Statistical analysis
The average and standard deviation of age and other parameters
were calculated for each group. The changes in the values of variousTable 1
Composition of herring-roe powder compared with placebo powder per 15 g.
Component Herring-roe Placebo
Calories (kcal) 70.2 62.6
Water (g) 0.11 0.26
Proteins (g) 12.3 1.73
Lipids (g) 2.30 0.93
Carbohydrates (g) 0.09 11.8
Ash (g) 0.23 0.29
Sodium (mg) 29.6 2.06
Docosahexaenoic acid (mg) 540 e
Eicosapentaenoic acid (mg) 300 eparameters were analyzed by Student's t-test. Statistical analyses
were performed with the program IBM SPSS Statistic 19 (IBM,
Armonk, NY). P values less than 0.05 were considered signiﬁcant.
3. Results
3.1. Effects of herring-roe powder on lipid metabolism
There were no signiﬁcant differences in age, body weight,
height, between the control and herring-roe groups (Table 2).
Although BMI and body fat was signiﬁcantly low in herring-roe
group compared to placebo group, it did not inﬂuence the result
of our clinical study. First, to determine the effect of herring-roe
powder on lipid metabolism, we measured total cholesterol (T-
Cho), high density lipoprotein cholesterol (HDL-Cho), LDL choles-
terol (LDL-Cho), arteriosclerosis index, triglyceride (TG), nonester-
iﬁed fatty acid (NEFA) (Fig. 3). T-Cho was signiﬁcantly decreased by
ingestion of placebo powder at the 8th week
(placebo: 9.44 ± 18.65 mg/dl, herring-roe: 4.65 ± 11.96 mg/dl, as
the change in the level of T-Cho from baseline to 8 weeks, P ¼ 0.01)
(Fig. 3a). However the herring-roe powder intake group improved
HDL-Cho compared with the placebo powder intake group at 8
weeks (placebo: 1.38 ± 5.94 mg/dl, herring-roe: 4.41 ± 4.96 mg/
dl, as the change in the level of HDL-Cho from baseline to 8 weeks,
P ¼ 0.01) (Fig. 3c). In addition, NEFA was decreased at 8 weeks by
the ingestion of herring-roe powder (placebo: 0.01 ± 0.14 mEq/l,
herring-roe: 0.12 ± 0.12 mEq/l, as the change in the level of NEFA
from baseline to 8 weeks, P ¼ 0.01) (Fig. 3f). There was no signiﬁ-
cant difference between the two groups of other lipid metabolism
parameters.
3.2. Effects of herring-roe powder on adiponectin and leptin
We also examined the effect of herring-roe powder on adipo-
nectin and leptin. Although no signiﬁcant between-group differ-
ences were observed in the level of serum adiponectin (Fig. 2a),
leptinwas slightly increased by herring-roe powder intake (Fig. 2b)
(placebo:0.44 ± 1.76 ng/ml, herring-roe: 0.69 ± 1.62 ng/ml, as the
change in the level of leptin from baseline to 8 weeks, P ¼ 0.06).
3.3. Levels of biomarkers of blood metabolism, liver and renal
function, glucose metabolism and body composition after the
ingestion of herring-roe powder
We examined the levels of several biomarkers of blood meta-
bolism, liver and renal function, and body composition. As shown in
Table 3, minimal changes were observed in the parameters of
glucose metabolism [fasting plasma glucose (FPG) and hemoglobin
A1c (HbA1c)], liver function [alkaline phosphatase (ALP), aspartate
aminotransferase (AST), alanine aminotransferase (ALT), lactate
dehydrogenase (LDH), and gamma glutamyl transpeptidase (g-
Fig. 1. Time schedule (in weeks) for this clinical study. Hematological measurements were conducted at baseline (0 week), the 4th week, the 6th week, and the 8th week.
Fig. 2. Changes in the level of adipokine from before to after herring-roe powder intake. Values are mean ± standard error (SE). Black bar; herring-roe powder, gray bar; placebo
powder. (a) Adiponectin. (b) Leptin.
Fig. 3. Changes in the level of lipid metabolism parameters from before to after herring-roe powder intake. Values are mean ± standard error (SE). Black bar; herring-roe powder,
gray bar; placebo powder. (a) Total cholesterol (T-Cho). (b) LDL cholesterol (LDL-Cho). (c) HDL cholesterol (HDL-Cho). (d) Arteriosclerosis index (e) Triglyceride (TG). (f) Nonesteriﬁed
fatty acid (NEFA).
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Table 3
Biochemical data.
0 week 4 weeks 6 weeks 8 weeks
FPG (mg/dL) Placebo 86.56 ± 9.04 86.2 ± 5.53 88.31 ± 6.15 85.19 ± 5.82
Herring-roe 88.29 ± 10.95 89.94 ± 13.15 87.41 ± 8.82 89.35 ± 8.97
HbA1c (%) Placebo 5.29 ± 0.26 5.3 ± 0.29 5.29 ± 0.28 5.26 ± 0.26
Herring-roe 5.34 ± 0.33 5.38 ± 0.34 5.37 ± 0.31 5.36 ± 0.32
BW (kg) Placebo 58.93 ± 10.34 58.48 ± 10.65 58.51 ± 10.31 58.45 ± 10.31
Herring-roe 52.39 ± 9.74 52.34 ± 9.93 52.27 ± 10.08 52.06 ± 10.12
BMI Placebo 23.04 ± 3.7 22.89 ± 3.81 22.83 ± 3.68 22.86 ± 3.69
Herring-roe 20.73 ± 2.08 20.69 ± 2.16 20.66 ± 2.2 20.58 ± 2.23
Body fat rate (%) Placebo 30.18 ± 7.57 29.72 ± 7.43 30.08 ± 7.29 30.19 ± 7.2
Herring-roe 25.21 ± 5.42 25.62 ± 4.69 25.12 ± 4.55 25.29 ± 4.8
AST (U/l) Placebo 22.06 ± 5.42 21.07 ± 3.54 20.94 ± 4.16 21.69 ± 5.59
Herring-roe 21.82 ± 4.69 21.12 ± 3.66 21.12 ± 3.77 20.65 ± 3.45
ALT (U/l) Placebo 17.88 ± 9.13 15.8 ± 5.78 16.38 ± 7.27 16.38 ± 8.32
Herring-roe 17.53 ± 5.44 17.12 ± 5.24 17.24 ± 5.29 16.94 ± 5.06
g-GTP (U/l) Placebo 30.44 ± 36.17 26.2 ± 30.82 31.44 ± 42.08 33.38 ± 44.08
Herring-roe 19.41 ± 9.13 20.00 ± 5.72 18.59 ± 4.62 19.18 ± 4.48
ALP (U/l) Placebo 182.69 ± 61.13 180.8 ± 60.04 181.19 ± 64.85 187.56 ± 70.23
Herring-roe 197.29 ± 48.82 194.53 ± 49.58 193.47 ± 49.15 200.53 ± 53.16
LDH (U/l) Placebo 220.94 ± 58.13 231.33 ± 63.50 219.38 ± 52.23 233.19 ± 50.35
Herring-roe 203.94 ± 25.80 212.00 ± 29.69 202.41 ± 17.92 208.76 ± 27.11
BUN (mg/dl) Placebo 13.52 ± 2.60 12.97 ± 3.72 14.24 ± 2.56 13.02 ± 2.86
Herring-roe 13.08 ± 3.72 14.31 ± 3.83 13.81 ± 3.47 14.18 ± 3.78
CRE (mg/dl) Placebo 0.71 ± 0.09 0.71 ± 0.10 0.74 ± 0.10 0.71 ± 0.09
Herring-roe 0.76 ± 0.14 0.73 ± 0.14 0.74 ± 0.14 0.76 ± 0.14
UA (mg/dl) Placebo 4.84 ± 1.08 4.86 ± 1.11 4.84 ± 1.27 4.98 ± 1.46
Herring-roe 5.04 ± 1.85 4.8 ± 2.09 4.84 ± 2.17 4.82 ± 1.94
Values are mean ± standard deviation (SD). FPG; fasting plasma glucose, HbA1c; hemoglobin A1c, BW; body weight, BMI; body mass index, ALP; alkaline phosphatase, AST;
aspartate aminotransferase, ALT; alanine aminotransferase, LDH; lactate dehydrogenase,g-GTP; gamma glutamyl transpeptidase, BUN; blood urea nitrogen, CRE; creatinine,
UA; ureic acid.
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(BUN), creatinine, and uric acid], and body composition [body
weight (BW), BMI, and body fat rate] occurred after the ingestion of
herring-roe powder, suggesting that the ingestion of herring-roe
powder has no or minimal unfavorable effects on these parame-
ters even at a dose of 15 g/day.
4. Discussion
The results of our randomized, double-blind, placebo-
controlled, parallel-group trial demonstrated the potential effects
of herring-roe powder on lipid metabolism. The level of HDL-Cho
was signiﬁcantly increased and the level of NEFA was signiﬁcantly
decreased by the 8-week ingestion of herring-roe powder. We also
observed that herring-roe powder slightly increased the level of
leptin. Taken together, these results suggest that herring-roe
powder improved dyslipidemia.
We observed no between-group differences in the levels of LDL-
Cho. Moreover, T-Cho was decreased by ingesting the placebo
powder compared to the herring-roe powder. However, HDL-Cho
was increased by ingesting the herring-roe powder compared to
the placebo powder. In addition, arteriosclerosis index tended to
improve by ingesting herring-roe powder (herring-
roe:0.02 ± 0.19, placebo: 0.07 ± 0.22, as the change in the level of
arteriosclerosis index from baseline to 6 weeks, P ¼ 0.23). Low
serum HDL-Cho is the risk factor of arteriosclerotic disease and
seems to be more important than high serum LDL-Cho.10 Herring-
roe powder intake may prevent arteriosclerotic disease to
improve HDL-Cho.
Moreover, herring-roe powder contained more amount of DHA
than EPA (DHA 540 mg and EPA 300 mg per day). A previous study
reported that DHA increased HDL-Cho and increased LDL-Cho.11
These facts suggest that DHA activated lipoprotein lipase (LPL)12
and facilitated degradation of TG, thereby converting very low
density lipoprotein (VLDL) to LDL.13 Moreover, Mori reported thatDHA induces the formation of a larger particle size of LDL.11 DHA
works to facilitate VLDL degradation by reduction of apolipoprotein
C-III, thereby decreasing small dense LDL.14 Small dense LDL has a
large speciﬁc gravity and easily penetrates the vascular wall.
Therefore, small dense LDL is a risk factor of dyslipidemia, arte-
riosclerosis, and cardiac disease.15 We need to perform a subclass
analysis of HDL-Cho and LDL-Cho to clarify the effects of herring-
roe powder to small dense LDL in vivo or in vitro.
In addition, NEFA was decreased by test meal intake compared
with placebo meal intake. NEFA secreted from enlarged adipocyte
inhibits the degradation of chylomicron and very low density li-
poprotein (VLDL); resulting in increased LDL-Cho. In a clinical
study, ingestion of herring-roe product contained 1738 mg DHA
and 616mg EPA per day for 14 days improved NEFA and HDL-Cho, a
ﬁnding that supports our present results.16 In addition, NEFA
inhibited glucose uptake to liver and skeletal muscle, thereby
causing insulin resistance.17 Herring-roe powder decreased NEFA,
facilitated glucose uptake, and is thereby expected to improve
blood glucose level and HbA1c. However, there were no differences
in fasting blood glucose level and HbA1c between herring-roe
powder and placebo powder. The reason for these results could
be that the blood glucose level and HbA1c of the subjects in this
clinical study were normal. We need further investigation of the
effects on glucose metabolism by herring-roe powder in subjects
with high blood glucose levels.
The serum leptin level was increased in herring-roe group,
although the increase was not signiﬁcant. Leptin is one of the
peptide hormones secreted from adipocytes. Leptin inhibits appe-
tite via the leptin receptor located in the hypothalamus.18 In addi-
tion, leptin increases glucose and fatty acid consumption, thus
preventing diabetes and obesity.19 A previous study reported that
mice fed with oil containing 5% herring-roe showed increased
serum leptin levels, although the increase was not signiﬁcant.20 In
our clinical study, herring-roe powder did not affect body weight
and body fat rates, indicating that herring-roe powder did not
M. Nishimura et al. / Journal of Traditional and Complementary Medicine 6 (2016) 247e251 251increase adipocyte. These results suggest that herring-roe powder
increases the secretion level of leptin through adipocyte. In addi-
tion, NEFA was decreased in subjects who ingested herring-roe
powder. These results suggest that the increase of leptin secretion
induced the consumption of NEFA. The mechanism of the increase
of leptin secretion was fully investigated; the herring-roe powder
intake improved lipid metabolism via increased energy consump-
tion and the inhibition of appetite via increased leptin secretion.
Although Shirai reported that adiponectin, another adipokine, was
improved by the intake of herring-roe oil,20 it was not changed in
our clinical study. Further investigation is required to study the
effects of adipokine, leptin, and adiponectin.
5. Conclusion
In our clinical study, herring-roe powder did not change uric
acid. Although we need to obtain more detailed data involving the
mechanism of improvement of lipid metabolism, the present study
suggests that the effective use of herring-roe can be beneﬁcial for
dyslipidemia without side effects.
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